PBAC's latest decision on Arginine: Not recommended (2017). Considered for Dietary management of urea cycle disorders (UCD).
PBAC outcome
Not recommended
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2017
Submissions
1
2017 → 2017
Eligible population
Patients with urea cycle disorders requiring dietary management with arginine supplementation.
Therapy area
Metabolic
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Comparator
Arginine 500
Economic model
Cost-minimisation
ICER note
Minor submission; no economic evaluation or ICER calculated.
Why PBAC said no
Reasons cited in the latest PSD: Clinically inappropriately high and undocumented protein content in the formulation, lack of clinical need for an additional formulation of arginine on the PBS, high protein levels (up to 20% of daily protein intake) could be detrimental to patients on highly restricted protein diets